Stem Cell Medicine Overview
Stem Cell Medicine is a biotechnology company developing second-generation cell therapy products as stand-alone treatments or in combination with pharmaceuticals, with a focus on neurological indications such as multiple sclerosis, pain, and neuromuscular injuries. The company also manages the production, registration, and marketing of its products.
Cumulative Funding Raised Over Time ($)
—Jan 2018
Latest News
Mammoth Times
growth-positive
Stem Cell Medicine Licenses Exosome Technology for Treating Autism from Ramot at Tel Aviv University
Stem Cell Medicine Ltd. has licensed an exosomes-based technology for the treatment of neurodegenerative and neuropsychiatric indications, specifically autism spectrum disorder (ASD). The technology was developed by Professor Dani Offen from Tel Aviv University. The first indication to be developed with the exosome technology is ASD, which represents a growing unmet medical need. SCM projects that a regulatory approved therapeutic based on the exosome technology would have blockbuster potential within five years. The company plans to fund the program by raising $30 million through partnerships and investment.
PartnersInvestment
growth-positive
Human Muscle Progenitor Cells Ectopically Expressing Neurotrophic Factors to Enhance Intrinsic Neuronal Regeneration
Stem Cell Medicine Ltd. (SCM) will present the results of a study on the use of genetically-modified muscle cells with neurotrophic factors to treat nerve injuries and neuropathic pain. The study shows promising results in alleviating motoric and sensory deficits in a mouse model. The technology was licensed to SCM in 2015 by Ramot at Tel Aviv University Ltd. and Yeda Research and Development Company Ltd. SCM plans to continue investing in this treatment and progress to Phase II trials for pain indications and other neurological diseases. The company focuses on developing second generation cell therapy products for neurological indications.
CustomersPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $5.5M |
| Last funding | $5.5M |
| Stage | Seed |
| Rounds | 2 |
| Investors | 1 |
Team Members
2
Employees: 11-50
Web & Social Links
| Website | www.stemcell-medicine.com |
Locations
Kiryat HaMada Street 5, Jerusalem, Israel
Photos & Videos
No files yet
Stem Cell Medicine Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyHealthcareProvidersCore Technology
BiologicalsCellsMoleculesTags (14)
biotechnologypharmaceuticalscell-therapymedical-technologiespharma-companiesstem-cellslaboratoriestherapeuticspersonalizationinflammatory-diseasestissue-regenerationneurologyautismtreatmentsGeographic Markets
ChinaUnited StatesIsraelGermanyStem Cell Medicine Financials
$5.5M
Total funding
Undisclosed
Capital raised
$5.5M
Last funding
Seed
Funding stage
2
Total rounds
1
Investors
Cumulative Funding Raised Over Time ($)
—Jan 2018
Private Equity Funding
Undisclosed Round
Jan 2018
Undisclosed
Crossroad Venture Capital Fund
Non-Equity Funding
GrantEvent
Mar 2019
$5.5M
The Israeli Ministry of Economy
Stem Cell Medicine Lifecycle
Cumulative Funding Raised Over Time
—Jan 2018
All Events
Undisclosed Round
Jan 2018
Undisclosed
Crossroad Venture Capital Fund
GrantEvent
Mar 2019
$5.5M
The Israeli Ministry of Economy
Stem Cell Medicine News
3 articlesMammoth Times
growth-positive
Stem Cell Medicine Licenses Exosome Technology for Treating Autism from Ramot at Tel Aviv University
Stem Cell Medicine Ltd. has licensed an exosomes-based technology for the treatment of neurodegenerative and neuropsychiatric indications, specifically autism spectrum disorder (ASD). The technology was developed by Professor Dani Offen from Tel Aviv University. The first indication to be developed with the exosome technology is ASD, which represents a growing unmet medical need. SCM projects that a regulatory approved therapeutic based on the exosome technology would have blockbuster potential within five years. The company plans to fund the program by raising $30 million through partnerships and investment.
PartnersInvestment
growth-positive
Human Muscle Progenitor Cells Ectopically Expressing Neurotrophic Factors to Enhance Intrinsic Neuronal Regeneration
Stem Cell Medicine Ltd. (SCM) will present the results of a study on the use of genetically-modified muscle cells with neurotrophic factors to treat nerve injuries and neuropathic pain. The study shows promising results in alleviating motoric and sensory deficits in a mouse model. The technology was licensed to SCM in 2015 by Ramot at Tel Aviv University Ltd. and Yeda Research and Development Company Ltd. SCM plans to continue investing in this treatment and progress to Phase II trials for pain indications and other neurological diseases. The company focuses on developing second generation cell therapy products for neurological indications.
CustomersPartners
Employee Info
| Employees (range) | 11-50 |
| Exact count | 14 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 12 classification IDs that could be used for matching.
Stem Cell Medicine Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 89/100 |
| Missing | video or image, markets, not claimed |
| BI Verification | Yotam Maman |
| Registrar ID | 514424712 |
| Crunchbase | stem-cell-medicine |
| Phone | +97225673292 |
| Last updater | Paul Weisko |
| Updater email | pweisko@gmail.com |
| Last update | 2021-04-21T00:00:00.000Z |
| Created | 2014-11-24T00:00:00.000Z |